Odonate Therapeutics
General Information | |
Business: |
We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors.
|
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 50 |
Founded: | 2013 |
Contact Information | |
Address | 4747 Executive Drive, Suite 510, San Diego, CA 92121, US |
Phone Number | (858) 731-8180 |
Web Address | http://www.odonate.com |
View Prospectus: | Odonate Therapeutics |
Financial Information | |
Market Cap | $645.4mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-18.9 mil (last 12 months) |
IPO Profile | |
Symbol | ODT |
Exchange | NASDAQ |
Shares (millions): | 6.3 |
Price range | $24.00 - $24.00 |
Est. $ Volume | $150.0 mil |
Manager / Joint Managers | Goldman Sachs/ Jefferies |
CO-Managers | Cowen |
Expected To Trade: | 12/7/2017 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |